Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Voyager Therapeutics (VYGR) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to -$0.47.

  • Voyager Therapeutics' EPS (Basic) fell 19375.0% to -$0.47 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.17, marking a year-over-year decrease of 41449.28%. This contributed to the annual value of -$1.13 for FY2024, which is 13668.83% down from last year.
  • Per Voyager Therapeutics' latest filing, its EPS (Basic) stood at -$0.47 for Q3 2025, which was down 19375.0% from -$0.57 recorded in Q2 2025.
  • Voyager Therapeutics' EPS (Basic)'s 5-year high stood at $3.05 during Q1 2023, with a 5-year trough of -$0.8 in Q2 2021.
  • In the last 5 years, Voyager Therapeutics' EPS (Basic) had a median value of -$0.51 in 2023 and averaged -$0.14.
  • In the last 5 years, Voyager Therapeutics' EPS (Basic) tumbled by 51333.33% in 2022 and then skyrocketed by 64464.29% in 2023.
  • Voyager Therapeutics' EPS (Basic) (Quarter) stood at $0.15 in 2021, then tumbled by 513.33% to -$0.62 in 2022, then skyrocketed by 298.39% to $1.23 in 2023, then crashed by 148.78% to -$0.6 in 2024, then grew by 21.67% to -$0.47 in 2025.
  • Its last three reported values are -$0.47 in Q3 2025, -$0.57 for Q2 2025, and -$0.53 during Q1 2025.